Of these patients, 1,284 met the inclusion criteria, 128 actively used a GLP-1RA, and 1,156 were not using a GLP-1RA
This comparative perspective juxtaposes the two compounds with respect to molecular pharmacology, clinical efficacy, safety, and potential clinical positioning, and proposes that, because resmetirom primarily targets hepatic lipid disposal whereas semaglutide unloads systemic caloric pressure, their complementary actions could be harnessed sequentially or in combination to achieve broader, more durable disease modification across the heterogeneous spectrum of patients with MASH
And it's important to note glutathione cannot prevent or treat COVID-19
Decreased stamina, loss of muscle mass, and weight gain may also occur